Menu
Search
|

Menu

Close
X

Aimmune Therapeutics Inc AIMT.OQ (NASDAQ Stock Exchange Global Select Market)

37.20 USD
-1.04 (-2.72%)
As of Feb 16
chart
Previous Close 38.24
Open 38.16
Volume 98,590
3m Avg Volume 169,580
Today’s High 38.55
Today’s Low 36.99
52 Week High 40.62
52 Week Low 15.97
Shares Outstanding (mil) 50.86
Market Capitalization (mil) 1,892.13
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 9 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-1.794
FY16
-1.883
FY15
-1.006
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.43
Price to Sales (TTM)
vs sector
--
8.57
Price to Book (MRQ)
vs sector
8.96
5.14
Price to Cash Flow (TTM)
vs sector
--
25.75
Total Debt to Equity (MRQ)
vs sector
0.00
15.12
LT Debt to Equity (MRQ)
vs sector
0.00
11.85
Return on Investment (TTM)
vs sector
-61.56
13.54
Return on Equity (TTM)
vs sector
-62.11
14.80

EXECUTIVE LEADERSHIP

Mark McDade
Independent Chairman of the Board, Since 2015
Salary: --
Bonus: --
Stephen Dilly
President, Chief Executive Officer, Director, Since 2016
Salary: $440,000.00
Bonus: $220,000.00
Eric Bjerkholt
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Jeffrey Knapp
Chief Operating Officer, Since 2016
Salary: $343,750.00
Bonus: $120,500.00
Susan Barrowcliffe
Senior Vice President, General Manager of Europe, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

8000 Marina Blvd Ste 300
BRISBANE   CA   94005-1884

Phone: +1650.6145220

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. The Company's lead CODIT product candidate, AR101, is an investigational biologic for the treatment of patients with peanut allergy. The Company has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101. The Company is in the process of evaluating additional delivery forms for AR101 for the maintenance phase.

SPONSORED STORIES